(Q48539541)

English

Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor

scientific article published in May 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16700881

Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16700881

type 2 diabetes

0 references

5

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16700881

author name string

Susumu Ogawa

1

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16700881

Kazuhisa Takeuchi

2

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16700881

Takefumi Mori

3

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16700881

Kazuhiro Nako

4

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16700881

publication date

1 May 2006

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16700881

Clinical and Experimental Pharmacology and Physiology

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16700881

33

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16700881

5-6

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16700881

477-479

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16700881

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04390.X

21 January 2018

Effectiveness of aldosterone blockade in patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04390.X

21 January 2018

Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04390.X

21 January 2018

Screening for cardiac dysfunction in asymptomatic patients by measuring B-type natriuretic peptide levels

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04390.X

21 January 2018

Identifiers

10.1111/J.1440-1681.2006.04390.X

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16700881

release_2ld5fd5ajvbmfg4zkyomb4gbr4

1 reference

https://api.fatcat.wiki/v0/release/2ld5fd5ajvbmfg4zkyomb4gbr4

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16700881

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48539541&oldid=2201518417"